SOLID TUMORS

This study tests a personalized vaccine made from a patient's own tumor mutations. It aims to train the immune system to fight advanced or high-risk solid tumors. Ten adults will receive the vaccine along with immune-boosting drugs. Researchers will check safety and whether the c…

This early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in people with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and watch for side effects. Up to 54 adults w…

This study tests a new drug called JAB-2485 in adults with advanced solid tumors (like breast or lung cancer) that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 102 participants will take the dr…

This study tests if dapagliflozin, a drug used for diabetes, can prevent kidney damage in people receiving platinum-based chemotherapy for solid tumors. About 46 participants will receive either dapagliflozin or a placebo, and researchers will measure kidney injury markers in uri…

This early-phase study tests a new drug called INCB123667, either by itself or combined with other cancer therapies, for people with advanced solid tumors that have not responded to standard treatments. The main goals are to find safe doses and check for side effects. About 604 a…

This early-phase study tests a new radioactive drug called Lutetium BL-ARC001 in 22 adults with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have …

This study tests a new drug, DPTX3186, in people with advanced solid tumors that have a specific genetic change (Wnt pathway activation) and no other treatment options. The main goals are to check the drug's safety, how the body processes it, and to look for early signs of tumor …

This early-phase study tests a new drug called CBA-1205, an antibody that targets a protein (DLK1) found on some cancer cells. The main goal is to check the drug's safety and find the right dose in about 66 adults with advanced solid tumors, including liver cancer and melanoma. P…

This study tests an experimental drug called M9140 in people with advanced solid tumors (gastric, lung, or pancreatic cancer) that have a specific protein called CEACAM5. The drug is designed to deliver a chemotherapy-like payload directly to cancer cells. The trial aims to see i…

This early-stage trial tests an investigational drug called JR8603 in about 94 adults with advanced solid tumors (including stomach, junction, and colorectal cancers) whose prior treatments have stopped working. The main goals are to check safety, find the best dose, and see if t…

This early-stage trial tests a new drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The main goals are to check the drug's safety and find the right dose. This study is not expected to cure…

This early-phase study tests a new drug called HRS-6208 in about 206 adults with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or…

This study tests an experimental drug called S-531011, alone or with other cancer treatments, in people with advanced solid tumors that have not responded to standard therapies. The goal is to find the safest dose and see if it can shrink tumors or slow cancer growth. About 282 p…

This early-phase study tests a new drug called BG-C0902 in people with advanced solid tumors that have not responded to other treatments. The drug is designed to target two cancer-related proteins (EGFR and MET) and deliver a chemotherapy-like payload directly to cancer cells. Th…

This early-stage study tests a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. This is a first-in-human trial, so research…

This study tests a new drug called 7MW4911 in 200 people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the best dose. This is the first time the drug is being tested in humans.

This study tests a new drug called ICP-723 in people with advanced solid tumors that cannot be removed by surgery. The goal is to check if the drug is safe, what dose works best, and how the body processes it. About 310 adults and adolescents are taking part.

This study is testing whether combining two drugs, envafolimab and lenvatinib, can shrink tumors in people with advanced solid tumors (like lung, kidney, or liver cancer) who have run out of standard options. About 170 adults will receive the combination to find the best dose and…

This early-phase study tests a new drug, BI 3923948, in adults with advanced solid tumors that have spread and are not responding to other treatments. The drug is given alone or with an immunotherapy (checkpoint inhibitor) to find the safest dose and see if it can shrink tumors. …

This study tests a new drug called RC278 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 312 adults aged 18 to 75 with good overall health are being recruite…

This study tests the safety and effectiveness of the drug ponatinib in children aged 1 to under 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to other treatments. The goal is to see if ponatinib can shrink or control the cancer. About…

This study tests a new drug called HRS-7058 combined with other anti-tumor medicines in 100 adults with solid tumors. The goal is to find a safe dose and see if the combination can shrink tumors. Participants must be 18-75, in good general health, and have a life expectancy of at…

This study looks at the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in people who have already been taking it in earlier studies. About 3,500 adults with solid tumors or blood cancers can join. The goal is to see how well the drug works over tim…

This early-stage study tests a new drug called AUBE00 in about 90 to 130 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must have a …

This study gives people with solid tumors who are already benefiting from encorafenib and/or binimetinib in earlier trials continued access to these medicines for up to 5 years. Participants must have been in a prior encorafenib/binimetinib study and still be getting benefit with…

This study tests a new drug called DCSZ11 combined with standard treatments in people with advanced or metastatic solid tumors. The goal is to see if the combination is safe and can shrink tumors or keep them from growing. About 9 adults with certain cancers, including head and n…

This phase 3 study tests whether adding the experimental drug INCB161734 to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS G12D mutation) live longer. About 588 adults who have not had prior treatment for metastatic disease will receiv…

This early-stage study tests an experimental drug called QTX3034 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goal is to check the drug's safety and find the right dose, either alone or with another drug called cetuximab. Abo…

This early-phase study tests a new drug (ORIC-114) combined with an existing targeted therapy (amivantamab) in people with advanced lung cancer that has a specific genetic change (EGFR exon20 insertion). The goal is to find the best dose and see if the combination is safe and can…

This early-phase study tests a new drug, XB371, in about 150 adults with advanced solid tumors that have come back or spread. The main goal is to check the drug's safety and find the right dose. Participants must be in fairly good health and have a life expectancy of at least 12 …

This early-stage trial tests a new cell treatment called GK01, given alone or with chemotherapy, for people with advanced solid tumors like pancreatic or stomach cancer. The main goal is to check safety and how the body handles the treatment. Only 15 participants will be enrolled…

This program offers early access to telisotuzumab adizutecan for people with solid tumors who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by local regula…

This study tests a new drug, JAB-30355, in adults with advanced solid tumors that have a specific change in the TP53 gene called Y220C. The goal is to see if the drug is safe, tolerable, and can shrink tumors. About 144 participants who have already tried at least one other cance…

This early-stage study tests a new oral drug, TYRA-430, in about 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes (FGF/FGFR pathway). The main goals are to find a safe dose and check for side effects. Researchers will also look for si…

This early-phase trial tests a new oral drug, Aza-TdC, in adults with advanced solid tumors that have not responded to standard treatments. The drug aims to reactivate genes that may slow tumor growth. The main goals are to find a safe dose and check for side effects.

This early-phase study tests a new drug called INCA33890 in about 408 adults whose solid tumors have spread or cannot be removed. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants must have tried other treatments first or be …

This study tests a new drug, BI 1703880, combined with ezabenlimab for adults with advanced solid tumors who have no other treatment options. The goal is to find the highest safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then e…

This early-phase study tests a new treatment called TX103 CAR-T cells in 85 adults with advanced solid tumors that have not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goal…

This study offers continued treatment with the cancer drug adagrasib to patients with advanced solid tumors who have already benefited from it in earlier studies. About 170 participants will receive the drug either alone or with other therapies, and researchers will monitor side …

This early-phase study tests a new drug called HDM2017 in about 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the drug a…

This study tests a new drug called SOA101, a special antibody designed to help the immune system attack cancer cells. It is for people with advanced solid tumors (like lung, ovarian, or breast cancer) who have no other treatment options. The study will check safety, find the best…

This study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if these combinations are safe and can shrink tumors. About 492 participants will take…

This early-phase study tests a new drug called casdatifan (AB521) in people with advanced kidney cancer or other solid tumors that haven't responded to standard treatments. The goal is to find safe doses and see how well the drug works alone or combined with other cancer therapie…

This early-phase study tests a new radioactive drug (lutetium [177Lu]-BL-ARC001) in 22 adults with advanced lung, breast, head/neck, or other solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug s…

This study tests a drug called FORE8394 (plixorafenib) in people with advanced solid tumors or brain tumors that have certain BRAF gene changes. The goal is to see if the drug can shrink tumors and control the disease. About 254 participants aged 10 and older will take the drug b…

This study tests a new drug called SHR-4610 in about 258 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. Participants will receive the drug and be closely…

This early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goals are to check the drug's safety and find the right dose. About 180 participants will take part to see if the drug …

This early-stage trial tests a new drug called HS-20110 in 475 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and see if the drug can shrink tumors. Researchers will also monitor side effects and how long …

This study tests a new treatment called B7H3 CAR-T cell therapy for people with advanced solid tumors that have a specific marker (B7H3). The therapy uses a patient's own immune cells, modified to better find and attack cancer cells. The main goals are to check if the treatment i…

This early-phase study tests a new drug, VLPONC-01, injected directly into head and neck tumors to see if it's safe and can shrink tumors. About 41 adults with advanced head and neck cancer will receive the injection alone or with an immunotherapy drug (pembrolizumab). The goal i…

This study tests a new drug called ABL103 combined with pembrolizumab (with or without a chemotherapy called taxane) in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and can shrink tumors or st…

This early-phase study tests a new drug called INCB161734, alone or with other cancer therapies, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 710 adults whose cancer ha…

This study tests an experimental drug called ZL-1310 in about 112 adults with advanced neuroendocrine carcinomas that have worsened after standard chemotherapy. The goal is to see if the drug can shrink tumors and to check for side effects. Participants will receive the drug and …

This early-stage trial tests a new drug, GEN1106, in about 103 people with solid tumors that have not responded to standard treatments. The study has three parts: first, finding a safe dose; then refining that dose; and finally, checking how well the drug works in a specific canc…

This early-phase study tests a new drug, BL-M24D1, in people with advanced digestive tract or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 33 adults will take part in this non-randomized tr…

This early-phase study tests a new drug called PEP08 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check safety, find the right dose, and see if the drug shows signs of shrinking tumors. About 40 adults who have tr…

This early-phase study is testing a new radioactive imaging agent called RT01-89Zr. It is designed to attach to a protein (TF) found on many solid tumor cells, so doctors can see the tumors on a PET/CT scan. The study will enroll about 10 adults with solid tumors to check the saf…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are getting chemotherapy. The drug aims to boost white blood cells, reducing the risk of severe infections. Researchers will monitor safety and how the drug works in the body.

This study is for people with solid tumor cancers who are receiving chemotherapy through a special tube called the RenovoCath catheter, which delivers drugs directly to the tumor. Researchers will track safety and how long patients live. The goal is to see how well this targeted …

This study is collecting medical information and biological samples from 15,000 people receiving radiation therapy for cancer at Mayo Clinic. Researchers will analyze how treatment affects side effects, quality of life, and survival. The goal is to improve future care by linking …

This study aims to find blood markers that could predict serious side effects from cancer immunotherapy. Researchers will measure interferon levels in 300 cancer patients starting immunotherapy and compare them to 40 people with autoimmune diseases like lupus. The goal is to deve…

This study aims to find abnormal genes (mutations) in cancer cells using leftover tumor tissue from past surgeries or biopsies. Participants also give a blood, cheek swab, or saliva sample for comparison. The goal is to learn which mutations matter for cancer survival and how the…

This study is testing a new combination of two drugs (SAR444881 and cemiplimab) in people with certain solid tumors, including lung, colorectal, and ovarian cancers. The main goal is to find biological markers that show how the drugs work, not to cure the disease. About 40 adults…